A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study

BACKGROUND: The InAdvance Study addresses the critical need for comprehensive data and biospecimen collection from individuals at elevated risk for cancer. Despite the existence of numerous biobanks in patients with cancer and individuals at average risk for cancer, a gap persists in resources targeting individuals with an elevated risk for cancer. METHODS: The InAdvance Study is longitudinally collecting biospecimens and health data from individuals with a range of cancer risk factors to facilitate collaborative research in cancer early detection and interception. Patient populations include those with pre-cancerous or precursor lesions (e.g. oral precursor lesions, Barrett's esophagus), hereditary cancer risk, personal or family history of cancer, or a history of exposures associated with cancer risk. Additionally, we are enrolling patients receiving multi-cancer early detection (MCED) tests, family members of elevated risk participants, and controls. Key goals include optimized biospecimen collection through standardized procedures, participant enrollment and engagement through an online platform, and standardized scalable procedures. Data is compiled into a central repository, and researchers can request access through a streamlined data request process. RESULTS: Since April 2023, 1,415 participants have enrolled in the study. 817 (58%) completed the baseline survey and 816 (58%) gave a baseline blood sample. CONCLUSION: The InAdvance Study's comprehensive approach provides a framework for basic, population, and translational studies to elucidate the molecular and environmental factors that drive cancer development. IMPACT: Comprehensive data and biospecimen biorepositories are critical to inform strategies for early detection, risk stratification, early interception for risk mitigation, and improved outcomes for higher-risk populations.

Authors

Institutions

Publication Details

Journal
Cancer Epidemiology Biomarkers & Prevention
Published
2026-04-30
DOI
https://doi.org/10.1158/1055-9965.epi-25-1684
Primary Topic
Health, Environment, Cognitive Aging
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study

Junne Kamihara, Tia L. Kauffman, Dipanjan Chowdhury, Matthew B.B. Yurgelun et al.
Cancer Epidemiology Biomarkers & Prevention
Health, Environment, Cognitive Aging
article

A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study

Junne Kamihara, Tia L. Kauffman, Dipanjan Chowdhury, Matthew B.B. Yurgelun, Kevin M. Elias, Tara Berman, Brian D. Crompton, Nicolette J. Rodriguez, Lisa Diller, Jenna B. Beckwith, Colleen M. Feltmate, Ana Babić, Elizabeth A. Mittendorf, Glenn J. Hanna, Sook‐Bin Woo, Sahand Hormoz, Kristen D. Brantley, Jacob M. Sands, Lachelle D. Weeks, Catherine R. Marinac, Bicky Thapa, Elizabeth O’Donnell, Kareem Adams, Timothy R Rebbeck, Giovanni Parmigiani, Sapna Syngal, Ann H Partridge, Narjust Florez, Irene Ghobrial, Nicole R Leboeuf, Judy E Garber
article en

Abstract

BACKGROUND: The InAdvance Study addresses the critical need for comprehensive data and biospecimen collection from individuals at elevated risk for cancer. Despite the existence of numerous biobanks in patients with cancer and individuals at average risk for cancer, a gap persists in resources targeting individuals with an elevated risk for cancer. METHODS: The InAdvance Study is longitudinally collecting biospecimens and health data from individuals with a range of cancer risk factors to facilitate collaborative research in cancer early detection and interception. Patient populations include those with pre-cancerous or precursor lesions (e.g. oral precursor lesions, Barrett's esophagus), hereditary cancer risk, personal or family history of cancer, or a history of exposures associated with cancer risk. Additionally, we are enrolling patients receiving multi-cancer early detection (MCED) tests, family members of elevated risk participants, and controls. Key goals include optimized biospecimen collection through standardized procedures, participant enrollment and engagement through an online platform, and standardized scalable procedures. Data is compiled into a central repository, and researchers can request access through a streamlined data request process. RESULTS: Since April 2023, 1,415 participants have enrolled in the study. 817 (58%) completed the baseline survey and 816 (58%) gave a baseline blood sample. CONCLUSION: The InAdvance Study's comprehensive approach provides a framework for basic, population, and translational studies to elucidate the molecular and environmental factors that drive cancer development. IMPACT: Comprehensive data and biospecimen biorepositories are critical to inform strategies for early detection, risk stratification, early interception for risk mitigation, and improved outcomes for higher-risk populations.

Cancer Epidemiology Biomarkers & Prevention
Brigham and Women's Hospital (US), Cleveland Clinic (US), The University of Texas MD Anderson Cancer Center (US), Harvard University (US), Harvard University Press (US), University of Massachusetts Boston (US), Dana-Farber Cancer Institute (US), Dana-Farber/Harvard Cancer Center (US), IIT@Harvard (US), Dana-Farber Brigham Cancer Center (US), Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US)
Openalex Percentile: Top 12%
Health, Environment, Cognitive Aging
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.